share_log

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

Benzinga Real-time News ·  Sep 23, 2022 22:01
  • Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ:SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero Therapeutics shares rose 7.3% to $2.37 on Friday.
  • Wolfe Research cut the price target for Salesforce, Inc. (NYSE:CRM) from $200 to $180. Wolfe Research analyst Alex Zukin maintained the stock with an Outperform. Salesforce shares fell 2.6% to $146.29 on Friday.
  • Benchmark cut the price target on Omnicell, Inc. (NASDAQ:OMCL) from $170 to $157. Omnicell shares fell 0.1% to $86.22 on Friday.
  • Morgan Stanley reduced the price target for Advanced Micro Devices, Inc. (NASDAQ:AMD) from $102 to $95. AMD shares fell 1.9% to $68.17 on Friday.
  • Piper Sandler lowered the price target on Accenture plc (NYSE:ACN) from $281 to $268. Accenture shares fell 1.5% to $258.39 on Friday.
  • BMO Capital lowered the price target for The Chemours Company (NYSE:CC) from $55 to $46. Chemours shares fell 4.3% to $25.51 on Friday.
  • RBC Capital cut the price target on AAR Corp. (NYSE:AIR) from $54 to $52. AAR shares fell 7.6% to $35.14 on Friday.

Check out this: Why Fear Level Among US Investors Is Increasing

Don't forget to check out our premarket coverage here .

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment